Imugene | Cancer Immunotherapies (@TeamImugene) / X

Imugene | Cancer Immunotherapies

1,664 posts

Imugene | Cancer Immunotherapies

@TeamImugene

A clinical stage immuno-oncology #biotech developing a range of new treatments seeking to activate the immune system of cancer patients. #Immunotherapy $IMU

Australia

Joined December 2015

Imugene | Cancer Immunotherapies
@TeamImugene
Jul 15, 2019
Our acquisition of the worldwide exclusive licence to a next-generation oncolytic virus (OV) technology, CF33, will include ex-Viralytics members as part of our project development team. Phase 1 clinical trial is anticipated to commence in 2020 #EndCancer imugene.com/oncolytic-virus
Imugene | Cancer Immunotherapies
@TeamImugene
Nov 2, 2021
Join us on Thursday, November 11, 10am AEST for our 'Science Series'. This session will feature our oncolytic #viraltherapy CHECKvacc with Professor Yuman Fong and Dr. Yuan Yuan. Register now: us02web.zoom.us/webinar/regist… $IMU @SoCalYuman @YuanYuanMDPhD #BreastCancer $IMU.ax #science
00:00
Imugene | Cancer Immunotherapies
@TeamImugene
Feb 10, 2024
Imugene was on the @SevenNetwork last night showcasing the potential of our #CF33 #oncolytic virus to target and fight various #cancers and #tumour types. A big thank you to the patients involved, Professor Yuman Fong for his scientific leadership, and @amberlaidler7 for
00:00
4.7K
Imugene | Cancer Immunotherapies
@TeamImugene
Aug 26, 2024
Deciphering the power of CAR T-cell therapy: This groundbreaking treatment is revolutionising cancer care by re-engineering T-cells to fight #cancer cells. Watch our video to understand how it works and why Imugene’s Allogeneic CAR-T cell therapy, azer-cel, has the potential to
00:00
42K
Imugene | Cancer Immunotherapies
@TeamImugene
Feb 13, 2025
We've reported further positive results from our Phase 1b clinical trial of azer-cel in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Two more patients in Cohort B have achieved a Complete Response, bringing the total to four out of seven evaluable patients. This
8.7K
Imugene | Cancer Immunotherapies
@TeamImugene
Nov 27, 2023
CF33 Oncolytic Virus We hope to improve the clinical benefits and quality of life for patients with cancers that are difficult to treat using current therapeutic approaches. Developed by Professor Yuman Fong at the prestigious City of Hope. Learn more imugene.com/oncolytic-virus
00:00
4.2K
Imugene | Cancer Immunotherapies
@TeamImugene
Jun 1, 2022
Learn more about our Oncolytic Virus CF33, invented by Professor Yuman Fong from City of Hope — and CHECKvacc, which is based on the CF33 platform with further enhanced tumour killing ability by adding an anti-PD-L1 antibody gene, which the virus delivers to the cancer cell. $IMU
00:00
Imugene | Cancer Immunotherapies
@TeamImugene
Mar 18, 2025
We've been granted Fast Track Designation by the U.S. FDA for our allogeneic CAR T-cell therapy, azer-cel, for the treatment of relapsed or refractory diffuse large B-cell lymphoma. This designation is designed to facilitate the development and expedite the review process for
00:00
2.8K
Imugene | Cancer Immunotherapies
@TeamImugene
Mar 2, 2023
“Having continued through the #monotherapy dose escalation unimpeded thus far, we’re eager to see #VAXINIA used in combination with the well-known Pembrolizumab drug and see the potential benefit this can bring to patients." - Leslie Chong, CEO $IMU More: bit.ly/3kCIhSO
23K
Imugene | Cancer Immunotherapies
@TeamImugene
Nov 9, 2023
“It is a great credit to our team that the Phase 1b study has been initiated and the first patient dosed, in under three months since acquiring the technology.” - CEO, Leslie Chong $IMU #CellTherapy #AZERCELL ASX news at imugene.com/announcements
5.2K
Imugene | Cancer Immunotherapies
@TeamImugene
Nov 27, 2023
“The Fast Track process of drug development is designed to facilitate the development, and the review of drugs to treat serious conditions and fill an unmet medical need, with Fast Track status often leading to earlier drug approval and access by patients.” - Leslie Chong $IMU
5.5K
Imugene | Cancer Immunotherapies
@TeamImugene
Jan 29, 2024
"This is the first treatment vaccine in any #gastrointestinal #cancer and we have high hopes that it will be very successful... It feels like we're on the cusp of something really big here with this vaccine, we're very excited," Dr Tony Dhillon said. 🗞️First bowel cancer vaccine
3.4K
Imugene | Cancer Immunotherapies
@TeamImugene
Dec 3, 2021
We are proud to announce, effective prior to the open of trading on December 20th, that Imugene Limited will enter into the S&P/ASX 200 Index. #FollowTheScience $IMU Read the S&P Dow Jones announcement: spglobal.com/spdji/en/docum…
Imugene | Cancer Immunotherapies
@TeamImugene
Jan 3, 2022
"I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial and we are now progressing to the Phase 1b combination studies in treatment naïve patients..." - Leslie Chong, CEO $IMU #FollowTheScience Learn more: bit.ly/3zAj5PX